688506 百利天恒
已收盘 07-22 15:00:00
资讯
新帖
简况
百利天恒(688506)7月19日主力资金净卖出948.03万元
证券之星 · 07-20 08:19
百利天恒(688506)7月19日主力资金净卖出948.03万元
广发基金吴兴武旗下广发保健A中报最新持仓,重仓百利天恒
证券之星 · 07-18
广发基金吴兴武旗下广发保健A中报最新持仓,重仓百利天恒
四川板块盘中拉升,百利天恒-U涨3.54%
自选股智能写手 · 07-18
四川板块盘中拉升,百利天恒-U涨3.54%
三年亏损超11亿元 科创板首富携百利天恒闯港股
新快报 · 07-16
三年亏损超11亿元 科创板首富携百利天恒闯港股
一周IPO观察:如祺、西锐上市,百利天恒AH递表,小氢未来SPAC上市
财经自媒体 · 07-15
一周IPO观察:如祺、西锐上市,百利天恒AH递表,小氢未来SPAC上市
新股前瞻丨百利天恒(688506.SH):靠一个BD能吃多久?
智通财经网 · 07-14
新股前瞻丨百利天恒(688506.SH):靠一个BD能吃多久?
7月12日百利天恒-U涨6.19%,广发医疗保健股票A基金重仓该股
证券之星 · 07-12
7月12日百利天恒-U涨6.19%,广发医疗保健股票A基金重仓该股
A股异动 | 拟港股上市,百利天恒反弹7%
港股那点事 · 07-12
A股异动 | 拟港股上市,百利天恒反弹7%
百利天恒港股上市面临双重考验:新药BL-B01D1研发挑战与预付款收入争议
和讯网 · 07-12
百利天恒港股上市面临双重考验:新药BL-B01D1研发挑战与预付款收入争议
科创板上市创新药企百利天恒谋划赴港二次IPO
每日经济新闻 · 07-12
科创板上市创新药企百利天恒谋划赴港二次IPO
百利天恒港交所IPO:仿制药研发生产起家,一项转让收入填平三年亏损
地产k线 · 07-12
百利天恒港交所IPO:仿制药研发生产起家,一项转让收入填平三年亏损
百利天恒-U大幅上涨 获北向资金连续4日增持
智选洞察 · 07-12
百利天恒-U大幅上涨 获北向资金连续4日增持
百利天恒三年亏11.6亿冲刺A+H 靠单品翻身盈利50亿或难持久
长江商报 · 07-12
百利天恒三年亏11.6亿冲刺A+H 靠单品翻身盈利50亿或难持久
单季盈利50亿之后,百利天恒又将冲刺港股,“科创板首富”还是缺钱?
蓝鲸财经 · 07-11
单季盈利50亿之后,百利天恒又将冲刺港股,“科创板首富”还是缺钱?
视频|一季度“豪赚”50亿元后,百利天恒赴港二次IPO
21世纪经济报道 · 07-11
视频|一季度“豪赚”50亿元后,百利天恒赴港二次IPO
百利天恒(688506.SH):注射用BL-M14D1(ADC)项目治疗晚期实体瘤获批I期临床试验
智通财经 · 07-11
百利天恒(688506.SH):注射用BL-M14D1(ADC)项目治疗晚期实体瘤获批I期临床试验
百利天恒拟港股上市:6款肿瘤药进入临床阶段,上半年获8亿美元授权交易首付款
澎湃新闻 · 07-11
百利天恒拟港股上市:6款肿瘤药进入临床阶段,上半年获8亿美元授权交易首付款
百利天恒: 《药物临床试验批准通知书》
每日经济新闻 · 07-11
百利天恒: 《药物临床试验批准通知书》
百利天恒递交港股上市申请,创新药企BD策略能否破解集采困局?
21世纪经济报道 · 07-11
百利天恒递交港股上市申请,创新药企BD策略能否破解集采困局?
“豪赚”50亿元还不够,百利天恒赴港二次IPO
21世纪经济报道 · 07-11
“豪赚”50亿元还不够,百利天恒赴港二次IPO
加载更多
公司概况
公司名称:
四川百利天恒药业股份有限公司
所属行业:
医药制造业
上市日期:
2023-01-06
主营业务:
四川百利天恒药业股份有限公司主营业务为药品的研发、生产及销售。公司主要产品包括:好好黄芪(黄芪颗粒)、新博柴黄(柴黄颗粒)、杜拉宝(消旋卡多曲颗粒)、新博林(利巴韦林颗粒)、奥博林(奥硝唑胶囊)、乐维静(丙泊酚注射液)、派斯欣(注射用甲磺酸帕珠沙星)等。公司获得了“四川省企业技术中心”、“高新技术企业”等。公司经过长期的行业和市场积累,逐步建立起良好的口碑和市场影响力,组建了完善的销售团队和销售体系,营销网络遍布全国30多个省、200余个地级市,实现了对不同地域的覆盖,以及“高—中—低”多层级市场的全面渗透。
发行价格:
24.70
{"stockData":{"symbol":"688506","market":"SH","secType":"STK","nameCN":"百利天恒","latestPrice":164.95,"timestamp":1721631600000,"preClose":160.72,"halted":0,"volume":1249472,"delay":0,"floatShares":90451000,"shares":401000000,"eps":10.9514,"marketStatus":"已收盘","marketStatusCode":5,"change":4.23,"latestTime":"07-22 15:00:00","open":159,"high":167.5,"low":158.4,"amount":205000000,"amplitude":0.0566,"askPrice":164.97,"askSize":2,"bidPrice":164.95,"bidSize":11,"shortable":0,"etf":0,"ttmEps":10.9514,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1721698200000},"adr":0,"adjPreClose":160.72,"symbolType":"stock_kcb","openAndCloseTimeList":[[1721611800000,1721619000000],[1721624400000,1721631600000]],"highLimit":176.79,"lowLimit":144.65,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":401000000,"pbRate":12.83,"roa":"--","roe":"188.56%","epsLYR":-1.95,"committee":-0.217391,"marketValue":66145000000,"floatMarketCap":14920000000,"peRate":15.062001,"changeRate":0.0263,"turnoverRate":0.0138,"status":0,"afterMarket":{"amount":0,"volume":0,"close":164.95,"buyVolume":0,"sellVolume":0,"time":1721633637153,"indexStatus":"已收盘 07-22 15:30:00","preClose":160.72}},"requestUrl":"/m/hq/s/688506","defaultTab":"news","newsList":[{"id":"2452227233","title":"百利天恒(688506)7月19日主力资金净卖出948.03万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2452227233","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2452227233?lang=zh_cn&edition=full","pubTime":"2024-07-20 08:19","pubTimestamp":1721434793,"startTime":"0","endTime":"0","summary":"证券之星消息,截至2024年7月19日收盘,百利天恒报收于160.72元,下跌3.11%,换手率1.04%,成交量9440.0手,成交额1.53亿元。近5日资金流向一览见下表:百利天恒融资融券信息显示,融资方面,当日融资买入792.11万元,融资偿还933.9万元,融资净偿还141.79万元。百利天恒主营业务:药品的研发、生产与营销。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024072000015909.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688506","BK0239"],"gpt_icon":0},{"id":"2452215021","title":"广发基金吴兴武旗下广发保健A中报最新持仓,重仓百利天恒","url":"https://stock-news.laohu8.com/highlight/detail?id=2452215021","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2452215021?lang=zh_cn&edition=full","pubTime":"2024-07-18 13:35","pubTimestamp":1721280949,"startTime":"0","endTime":"0","summary":"证券之星消息,7月18日广发基金旗下吴兴武管理的广发医疗保健股票型基金公布中报,近1年净值增长率-17.01%。与上一季度相比,该基金前十大重仓股新增诺泰生物,科伦药业,泽璟制药,江中药业,同仁堂;其中百利天恒持仓占比8.22%,为该基金第一大重仓股;太极集团,国际医学,昆药集团,信立泰,九洲药业等退出前十大重仓股;详细数据如下:以上内容由证券之星根据公开信息整理,由算法生成(网信算备310104345710301240019号),与本站立场无关,如数据存在问题请联系我们。本文为数据整理,不对您构成任何投资建议,投资有风险,请谨慎决策。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024071800025746.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688506"],"gpt_icon":0},{"id":"2452914928","title":"四川板块盘中拉升,百利天恒-U涨3.54%","url":"https://stock-news.laohu8.com/highlight/detail?id=2452914928","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2452914928?lang=zh_cn&edition=full","pubTime":"2024-07-18 09:58","pubTimestamp":1721267919,"startTime":"0","endTime":"0","summary":"07月18日,四川板块盘中拉升,截至09点58分,四川板块整体指数上涨0.55%,报2960.650点。从个股上来看,该板块的成分股中,百利天恒-U涨3.54%,富临运业、苑东生物、ST升达涨幅居前。从资金上来看,截止发稿,四川板块主力净流入为-2.95亿,其中五 粮 液受到资金热捧,主力净流入3693.26万;拉长时间线来看,该板块近20日主力资金净流入-106.78亿。(以上内容为腾讯自选股基于公开消息,由程序或算法智能生成,仅作为用户看盘参考,不作为投资建议或交易依据。股市有风险,请谨慎决策。)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407180958399681de47&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407180958399681de47&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688506","BK0239"],"gpt_icon":0},{"id":"2451498308","title":"三年亏损超11亿元 科创板首富携百利天恒闯港股","url":"https://stock-news.laohu8.com/highlight/detail?id=2451498308","media":"新快报","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2451498308?lang=zh_cn&edition=full","pubTime":"2024-07-16 08:40","pubTimestamp":1721090453,"startTime":"0","endTime":"0","summary":"在售药品销售下滑,创新药物未获准上市新快报讯 近日,已在科创板上市的四川百利天恒药业股份有限公司(下称“百利天恒”)递表港交所。2021年-2023年,百利天恒累计亏损超11亿元,公司新药 ...","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://stock.10jqka.com.cn/hks/20240716/c659835407.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun","symbols":["BK0239","159982","688506"],"gpt_icon":0},{"id":"2451669686","title":"一周IPO观察:如祺、西锐上市,百利天恒AH递表,小氢未来SPAC上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2451669686","media":"财经自媒体","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2451669686?lang=zh_cn&edition=full","pubTime":"2024-07-15 10:57","pubTimestamp":1721012220,"startTime":"0","endTime":"0","summary":"港股IPO观察截止2024年的第28周,港交所6只新股上市,2只新股招股,1只新股通过聆讯,1家递交招股书。百利天恒递交IPO招股书7月10日,四川百利天恒药业在港交所递交招股书,拟在香港主板上市。据此,百利天恒将与百时美施贵宝进行全球战略合作,共同开发及共同商业化BL-B01D1。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/jjxw/2024-07-15/doc-inceerfi5131844.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/jjxw/2024-07-15/doc-inceerfi5131844.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["688506","BK0239","02507"],"gpt_icon":0},{"id":"2451576680","title":"新股前瞻丨百利天恒(688506.SH):靠一个BD能吃多久?","url":"https://stock-news.laohu8.com/highlight/detail?id=2451576680","media":"智通财经网","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2451576680?lang=zh_cn&edition=full","pubTime":"2024-07-14 20:55","pubTimestamp":1720961718,"startTime":"0","endTime":"0","summary":"核心产品获84亿美金BD,市值拉满的百利天恒赴港能否复制A股一年4倍的走势?","market":"hk","thumbnail":"https://img.zhitongcaijing.com/image/20240714/20240714205557_30862.png?x-oss-process=image/format,jpg/quality,Q_80","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20240714/20240714205557_30862.png?x-oss-process=image/format,jpg/quality,Q_80"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1150652.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["688506","BK0239"],"gpt_icon":0},{"id":"2450370720","title":"7月12日百利天恒-U涨6.19%,广发医疗保健股票A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2450370720","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2450370720?lang=zh_cn&edition=full","pubTime":"2024-07-12 16:15","pubTimestamp":1720772154,"startTime":"0","endTime":"0","summary":"证券之星消息,7月12日百利天恒-U涨6.19%,收盘报172.0元,换手率1.67%,成交量1.51万手,成交额2.57亿元。重仓百利天恒-U的前十大公募基金请见下表:该股最近90天内共有3家机构给出评级,买入评级2家,增持评级1家;过去90天内机构目标均价为209.3。根据2024基金Q1季报公募基金重仓股数据,重仓该股的公募基金共39家,其中持有数量最多的公募基金为广发医疗保健股票A。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024071200030568.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688506","BK0239"],"gpt_icon":0},{"id":"2450379399","title":"A股异动 | 拟港股上市,百利天恒反弹7%","url":"https://stock-news.laohu8.com/highlight/detail?id=2450379399","media":"港股那点事","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2450379399?lang=zh_cn&edition=full","pubTime":"2024-07-12 14:46","pubTimestamp":1720766760,"startTime":"0","endTime":"0","summary":"格隆汇7月12日|百利天恒(688506.SH)拉升反弹7%,报172.69元,总市值692亿元。7月10日,百利天恒向港交所递交上市申请,联席保荐人为高盛、摩根大通、中信证券。从过往年度财务数据看,百利天恒已经有药品销售收入,但尚未盈利。今年3月,百利天恒宣布,已收到与百时美施贵宝就BL-B01D1项目开发与商业化许可协议8亿美元首付款,约57亿元人民币,预计该款项将对2024年业绩产生积极影响。\n\n\n海量资讯、精准解读,尽在新浪财经APP","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/bxjj/2024-07-12/doc-inccweiv7823406.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/bxjj/2024-07-12/doc-inccweiv7823406.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0239","HSCEI","YANG","399300","688506","HSTECH","07226","159982"],"gpt_icon":0},{"id":"2450326592","title":"百利天恒港股上市面临双重考验:新药BL-B01D1研发挑战与预付款收入争议","url":"https://stock-news.laohu8.com/highlight/detail?id=2450326592","media":"和讯网","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2450326592?lang=zh_cn&edition=full","pubTime":"2024-07-12 11:04","pubTimestamp":1720753484,"startTime":"0","endTime":"0","summary":"近日,百利天恒发布公告称,公司申请境外公开发行股票(H股)并在香港联交所主板上市有了新进展。公司已于2024年7月10日向香港联交所递交了本次发行的申请,并于同日在香港联交所网站刊登了 ...","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://stock.10jqka.com.cn/hks/20240712/c659750267.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun","symbols":["BK0239","688506"],"gpt_icon":0},{"id":"2450932342","title":"科创板上市创新药企百利天恒谋划赴港二次IPO","url":"https://stock-news.laohu8.com/highlight/detail?id=2450932342","media":"每日经济新闻","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2450932342?lang=zh_cn&edition=full","pubTime":"2024-07-12 10:52","pubTimestamp":1720752720,"startTime":"0","endTime":"0","summary":"7月10日,科创板上市创新药企业百利天恒向港交所主板提交上市申请,高盛、摩根大通、中信证券为其联席保荐人。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240712105236af91f980&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240712105236af91f980&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","159992","688506","159982"],"gpt_icon":0},{"id":"2450426323","title":"百利天恒港交所IPO:仿制药研发生产起家,一项转让收入填平三年亏损","url":"https://stock-news.laohu8.com/highlight/detail?id=2450426323","media":"地产k线","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2450426323?lang=zh_cn&edition=full","pubTime":"2024-07-12 10:27","pubTimestamp":1720751236,"startTime":"0","endTime":"0","summary":"据悉,百利天恒于2023年1月6日在上海科创板上市,当时以每股人民币24.70元发行4010万股,募资约9.90亿元,保荐机构、主承销商为安信证券股份有限公司。百利天恒成立于1996年,以仿制药研发生产起家,由董事长、总经理兼首席科学官朱义博士创立。2024年前4个月,百利天恒收入54.97亿元,同比增长3691%;2021年至2023年,百利恒天三年连续亏损,总计亏损约11.7亿元。仅BMS一笔交易的预付款就填平了百利天恒过去三年的亏损。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024071210421495aa4fa1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024071210421495aa4fa1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","688506"],"gpt_icon":0},{"id":"2450342919","title":"百利天恒-U大幅上涨 获北向资金连续4日增持","url":"https://stock-news.laohu8.com/highlight/detail?id=2450342919","media":"智选洞察","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2450342919?lang=zh_cn&edition=full","pubTime":"2024-07-12 09:43","pubTimestamp":1720748592,"startTime":"0","endTime":"0","summary":"资金动向截止发稿,百利天恒-U获得主力净流入533万元,其中超大单流入387万元,大单流入145万元。北向资金方面,百利天恒-U07月11日获得北向资金增持14.34万股,连续4日增持,截至07月11日,北向资金当前共持有百利天恒-U102.27万股,市值1.75亿元,持股占流通股比为1.13%。主营业务及业绩百利天恒-U公司主营业务为药品的研发、生产及销售。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240712094538af91f540&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240712094538af91f540&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688506","BK0239"],"gpt_icon":0},{"id":"2450345843","title":"百利天恒三年亏11.6亿冲刺A+H 靠单品翻身盈利50亿或难持久","url":"https://stock-news.laohu8.com/highlight/detail?id=2450345843","media":"长江商报","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2450345843?lang=zh_cn&edition=full","pubTime":"2024-07-12 08:10","pubTimestamp":1720743013,"startTime":"0","endTime":"0","summary":"百利天恒2023年1月在科创板上市。2023年,百利天恒在科创板上市的首年,公司营业收入5.62亿元,同比下降20.11%;净利润亏损7.80亿元,同比下降176.40%。由此,百利天恒营业收入已连续四年下降,净利润也连续三年亏损,累计亏损11.62亿元。截至2023年末,百利天恒资产负债率达89.34%,较上年同期53.10%增长36.24个百分点。因此,2024年一季度,百利天恒业绩大涨,公司实现营业收入54.62亿元,同比增长4325.45%;净利润50.05亿元,同比增长3100.16%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024071208172895a993f4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024071208172895a993f4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","688506"],"gpt_icon":0},{"id":"2450364224","title":"单季盈利50亿之后,百利天恒又将冲刺港股,“科创板首富”还是缺钱?","url":"https://stock-news.laohu8.com/highlight/detail?id=2450364224","media":"蓝鲸财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2450364224?lang=zh_cn&edition=full","pubTime":"2024-07-11 23:04","pubTimestamp":1720710243,"startTime":"0","endTime":"0","summary":"2023年初,百利天恒登陆科创板,上市之后,公司股价持续上涨,一度创出每股215.71元的高点,较发行价飙升近8倍,创始人朱义一度每股成为“科创板首富”,以417亿元的身价登上2024新财富500创富榜。百利天恒上市初期,公司流通股仅有3306.33万股。解禁后,百利天恒的第二大、第三大股东先后减持套现。今年3月7日,百利天恒收到BMS支付的8亿美元首付款。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024071123041095a6f35a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024071123041095a6f35a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","688506","159982"],"gpt_icon":0},{"id":"2450355477","title":"视频|一季度“豪赚”50亿元后,百利天恒赴港二次IPO","url":"https://stock-news.laohu8.com/highlight/detail?id=2450355477","media":"21世纪经济报道","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2450355477?lang=zh_cn&edition=full","pubTime":"2024-07-11 19:15","pubTimestamp":1720696500,"startTime":"0","endTime":"0","summary":"7月10日,据港交所官网,四川百利天恒药业股份有限公司正式提交港交所上市申请书,拟赴港上市。百利天恒招股书显示,其前身百利药业成立于1996年。值得一提的是,百利天恒已于2023年1月在上交所科创板成功上市,此次是百利天恒赴港再度冲击IPO。2024年一季度,百利天恒营业收入达54.62亿元,同比暴增4325%;净利润50.05亿元,同比暴增3100.16%。截至7月11日收盘,百利天恒总市值为649.5亿元。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/roll/2024-07-11/doc-inccumyt5157859.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2024-07-11/doc-inccumyt5157859.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["688506","BK0239"],"gpt_icon":0},{"id":"2450337763","title":"百利天恒(688506.SH):注射用BL-M14D1(ADC)项目治疗晚期实体瘤获批I期临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2450337763","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2450337763?lang=zh_cn&edition=full","pubTime":"2024-07-11 18:45","pubTimestamp":1720694733,"startTime":"0","endTime":"0","summary":"智通财经APP讯,百利天恒(688506.SH)发布公告,公司于近日收到国家药品监督管理局(NMPA)正式批准签发的《药物临床试验批准通知书》,公司自主研发的创新生物药BL-M14D1(ADC)的药物临床试验获得批准。BL-M14D1是与BL-B01D1出自同一小分子技术平台、与BL-B01D1共享同一“连接子+毒素”平台的ADC药物,其适应症为晚期实体瘤。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1149526.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","BL","BK4231","BK1583","BK1141","ADC","LU1815336091.USD","BK4080","688506","03347","LU0757428866.USD","BK4023","BK1576"],"gpt_icon":0},{"id":"2450453337","title":"百利天恒拟港股上市:6款肿瘤药进入临床阶段,上半年获8亿美元授权交易首付款","url":"https://stock-news.laohu8.com/highlight/detail?id=2450453337","media":"澎湃新闻","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2450453337?lang=zh_cn&edition=full","pubTime":"2024-07-11 18:42","pubTimestamp":1720694520,"startTime":"0","endTime":"0","summary":"7月10日,百利天恒向港交所递交上市申请,联席保荐人为高盛、摩根大通、中信证券。让百利天恒在行业名声大噪的是一笔授权交易。管线中的创新药是百利天恒未来发展的重要支撑,目前已进入临床阶段的有6款ADC药物,核心管线正是被BMS看重的BL-B01D1。加入百利天恒前,朱海还在2019年6月至2019年8月任FDA药品评价和研究中心研究员。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024071118432895a5a0f8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024071118432895a5a0f8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","688506"],"gpt_icon":0},{"id":"2450337456","title":"百利天恒: 《药物临床试验批准通知书》","url":"https://stock-news.laohu8.com/highlight/detail?id=2450337456","media":"每日经济新闻","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2450337456?lang=zh_cn&edition=full","pubTime":"2024-07-11 18:36","pubTimestamp":1720694208,"startTime":"0","endTime":"0","summary":"每经AI快讯,百利天恒 7月11日晚间发布公告称,四川百利天恒药业股份有限公司于近日收到国家药品监督管理局正式批准签发的《药物临床试验批准通知书》。公司自主研发的创新生物药BL-M14D1的药物临床试验获得批准。2023年1至12月份,百利天恒的营业收入构成为:医药制造业占比99.74%。截至发稿,百利天恒市值为650亿元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407111837089f33f988&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407111837089f33f988&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688506","BK0239"],"gpt_icon":0},{"id":"2450332789","title":"百利天恒递交港股上市申请,创新药企BD策略能否破解集采困局?","url":"https://stock-news.laohu8.com/highlight/detail?id=2450332789","media":"21世纪经济报道","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2450332789?lang=zh_cn&edition=full","pubTime":"2024-07-11 18:14","pubTimestamp":1720692840,"startTime":"0","endTime":"0","summary":"21世纪经济报道记者季媛媛 上海报道 在一季度“豪赚”50亿元后,已在科创板上市的百利天恒正式提交港交所上市申请书,拟赴港上市。7月10日,据港交所官网,四川百利天恒药业股份有限公司正式提交港交所上市申请书,拟赴港上市。百利天恒想要打破集采承压的局面,赴港上市聚焦创新投入,被认为是一条需要选择的路径。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/roll/2024-07-11/doc-inccufsy8516045.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2024-07-11/doc-inccufsy8516045.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["07226","159992","06978","YANG","BK0239","HSTECH","BK1574","BK1161","688506","HSCEI"],"gpt_icon":0},{"id":"2450334642","title":"“豪赚”50亿元还不够,百利天恒赴港二次IPO","url":"https://stock-news.laohu8.com/highlight/detail?id=2450334642","media":"21世纪经济报道","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2450334642?lang=zh_cn&edition=full","pubTime":"2024-07-11 17:53","pubTimestamp":1720691580,"startTime":"0","endTime":"0","summary":"2024年7月10日,百利天恒赴港IPO申请获得受理,联席保荐人为高盛、摩根大通、中信证券。赴港二次IPO储备资金值得一提的是,百利天恒已于2023年1月在上交所科创板成功上市,此次是百利天恒赴港再度冲击IPO。2024年6月21日,百利天恒发布公告称,董事会已审议通过《关于公司发行H股股票并在香港联合交易所有限公司上市的议案》等,将在股东大会决议有效期内选择适当的时机和发行窗口完成本次发行H股并上市。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/roll/2024-07-11/doc-inccufst8462864.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2024-07-11/doc-inccufst8462864.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0239","688506"],"gpt_icon":0}],"profile":{"ret":0,"listingDate":"2023-01-06","address":"四川省成都市温江区成都海峡两岸科技产业园百利路161号一幢一号","stockEarnings":[{"period":"1week","weight":-0.0123},{"period":"1month","weight":-0.1484},{"period":"3month","weight":0.231},{"period":"6month","weight":0.4152},{"period":"1year","weight":1.0364},{"period":"ytd","weight":0.1791}],"companyName":"四川百利天恒药业股份有限公司","boardCode":"AI0027","perCapita":"29462股","boardName":"医药制造业","registeredCapital":"40100万元","compareEarnings":[{"period":"1week","weight":-0.0033},{"period":"1month","weight":-0.0113},{"period":"3month","weight":-0.0191},{"period":"6month","weight":0.0509},{"period":"1year","weight":-0.0642},{"period":"ytd","weight":-0.0036}],"survey":" 四川百利天恒药业股份有限公司主营业务为药品的研发、生产及销售。公司主要产品包括:好好黄芪(黄芪颗粒)、新博柴黄(柴黄颗粒)、杜拉宝(消旋卡多曲颗粒)、新博林(利巴韦林颗粒)、奥博林(奥硝唑胶囊)、乐维静(丙泊酚注射液)、派斯欣(注射用甲磺酸帕珠沙星)等。公司获得了“四川省企业技术中心”、“高新技术企业”等。公司经过长期的行业和市场积累,逐步建立起良好的口碑和市场影响力,组建了完善的销售团队和销售体系,营销网络遍布全国30多个省、200余个地级市,实现了对不同地域的覆盖,以及“高—中—低”多层级市场的全面渗透。","serverTime":1721674424735,"listedPrice":24.7,"stockholders":"3070人(较上一季度增加3.16%)","compareStock":{"symbol":"000001.SH","name":"上证指数"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.25.1","shortVersion":"4.25.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"百利天恒(688506)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供百利天恒(688506)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"百利天恒,688506,百利天恒股票,百利天恒股票老虎,百利天恒股票老虎国际,百利天恒行情,百利天恒股票行情,百利天恒股价,百利天恒股市,百利天恒股票价格,百利天恒股票交易,百利天恒股票购买,百利天恒股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"百利天恒(688506)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供百利天恒(688506)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}